October 18, 2021

Medical Trend

Medical News and Medical Resources

Nature:  Nano-drug carriers have organ selectivity for delivery of mRNA and CRISPR gene editing

Nature:  Nano-drug carriers have organ selectivity for delivery of mRNA and CRISPR gene editing

Nature:  Nano-drug carriers have organ selectivity for delivery of mRNA and CRISPR gene editing.  This research has developed a series of new phospholipids that are easy to break the membrane, expand the types and structures of phospholipids, and broaden the LNPs system. It proves that both the regulation of lipid chemical structure and the regulation of nanoparticle components can achieve organ selectivity, which provides ideas for the development of next-generation gene vectors, which will greatly promote organ-specificity based on mRNA delivery and CRISPR/Cas gene editing Research on the treatment of sexual diseases.

In recent years, mRNA-based protein replacement therapy and CRISPR/Cas-mediated gene editing have great application prospects in the treatment of many diseases. In particular, the mRNA COVID-19 vaccine developed by Moderna and Pfizer/BioNtech has been successfully applied recently. Emmanuelle Charpentier and Jennifer A. Doudna won the 2020 Nobel Prize in Chemistry for their “CRISPR/Cas9 gene editing technology”. However, safe and effective in vivo delivery is still the biggest obstacle restricting the application of gene therapy.

In the field of RNA delivery, Lipid nanoparticles (LNP) have made outstanding achievements. The first siRNA drug (Onpattro) approved by the FDA in 2018 and the above two mRNA COVID-19 vaccines both use a lipid nanoparticle (LNP) delivery system.

Although the existing research work has made some progress, we still need a more efficient and intelligent in vivo delivery system. In particular, 1) The most efficient LNPs system at present, only 1%-4% of RNA escapes endosomes, and endosome escape performance is low; 2) Most of the existing LNPs have liver-targeting, which is not the liver. The problem of targeted and specific delivery needs to be solved urgently.

On February 4, 2021, the team of Professor Daniel J. Siegwart from the University of Texas Southwestern Medical Center (Joint One as Dr. Shuai Liu and Dr. Qiang Cheng) published an online title on Nature Materials: Membrane destabilizing ionizable phospholipids for organ Research papers on selective mRNA delivery and CRISPR-Cas gene editing.


Reported the synthesis of a series of new phospholipids (iPhos) with strong endosomal escape properties. LNPs (denoted as iPLNPs) containing iPhos components are used to deliver mRNA or Cas9 mRNA/sgRNA) complexes, achieving extremely high in vivo mRNA delivery and CRISPR/Cas gene editing efficiency. In addition, the control of iPhos phospholipid chemical structure or the control of iPLNPs components can achieve selective organ delivery.

Nature:  Nano-drug carriers have organ selectivity for delivery of mRNA and CRISPR gene editing


LNPs are usually composed of phospholipids/cationic lipids/cholesterol/pegylated lipids. Almost all previous studies have focused on optimizing the structure of cationic lipids, but the current commercial phospholipids have a single type and structure.
However, phospholipids have their unique advantages. Phospholipids have the same structure as biological membranes and have strong endosomal membrane fusion and endosomal escape potential. Therefore, new phospholipids with controllable structures can be flexibly designed by chemical means to obtain a more efficient LNPs system. Provides a new idea.

The author speculates that a zwitterionic head composed of a tertiary amine and a phosphate group, combined with a tail with three hydrophobic alkyl chains, will facilitate the escape of phospholipid endosomes (Figure 1).

 Nature:  Nano-drug carriers have organ selectivity for delivery of mRNA and CRISPR gene editing
Figure 1. The new phospholipid iPhos facilitates the phase transition of endosomal membranes, thereby improving endosomal escape performance.


In an acidic endosomal environment, the tertiary amine is protonated, and the phospholipid forms a smaller zwitterionic head and a larger multi-hydrophobic chain tail, which is inserted into the phospholipid membrane to form a cone structure, which promotes the membrane to transform into a hexagonal crystal phase. Achieve endosomal escape. At a neutral physiological pH, the negatively charged iPhos is difficult to insert into the endosomal membrane, which ensures the low toxicity of the iPhos material. In order to verify this theory, the author designed and synthesized 572 iPhos phospholipids (Figure 2), which contain various amphiphilic heads and different numbers of hydrophobic chain tails. In vitro structure-activity relationship results and membrane phase transition studies have effectively supported the above theory.

 

Nature:  Nano-drug carriers have organ selectivity for delivery of mRNA and CRISPR gene editing
Figure 2. Synthesis of 572 iPhos and in vitro mRNA delivery screening.


Next, the authors further screened for mRNA delivery in vivo. The structure-activity relationship in vivo revealed very interesting conclusions. The structure of iPhos not only affects transfection efficiency in vivo, but also controls organ selectivity.

The result shows:

1) iPhos with one ionizable tertiary amine, one negatively charged phosphoric acid group and three hydrophobic alkyl chains has the highest efficiency;

2) The length of the alkyl chain on one side of the tertiary amine controls the efficiency of mRNA delivery in vivo, and the 8-10 carbon chain length iPhos has the highest efficiency in vivo;

3) The length of the alkyl chain on the phosphate side determines the organ selectivity. iPhos with a length of 9 to 12 carbon chain delivers mRNA to the liver for expression, and the iPhos with a length of 13 to 16 carbon chain delivers mRNA to the spleen for expression. This interesting phenomenon indicates that regulating the chemical structure of iPhos can achieve organ selectivity, which is of reference significance for the design of other delivery systems.

In 2020, Professor Siegwart’s team developed an organ selective targeting (SORT) technology, which has great potential in the application of mRNA delivery and CRISPR/Cas gene editing. The related results were published in Nature Nanotechnology.

Using SORT technology for reference, the author focused on the optimized iPhos 9A1P9, assisted with various lipids, and realized organ-specific mRNA delivery on the premise of ensuring high mRNA delivery efficiency: 9A1P9 bound zwitterionic lipids (DOPE) ), which mediates the expression of mRNA in the spleen; 9A1P9 binds to ionizable cationic lipids (MDOA, DODAP or 5A2-SC8) so that mRNA is expressed in the liver; 9A1P9 binds to non-ionizable cationic lipids (DOTAP or DDAB) to achieve mRNA is expressed in the lung.

It is worth mentioning that 9A1P9-5A2-SC8 iPLNPs have reached the upper limit of chemiluminescence detection by small animal in vivo imaging systems at a dose as low as 0.05 mg/kg Fluc mRNA. The mRNA delivery efficiency of 9A1P9 is 40 to 965 times that of commercial phospholipids DOPE and DSPC.


Then, the author used FDA-approved DLin-MC3-DMA LNPs (siRNA drug Onpattro) As a positive control, the efficiency of 9A1P9-5A2-SC8 iPLNPs in delivering mRNA in vivo was 13 times that of DLin-MC3-DMA LNPs. These research results fully proved the excellent performance of iPhos in mRNA delivery.

Subsequently, the authors used liver-targeted 9A1P9-5A2-SC8 iPLNPs and lung-targeted 9A1P9-DDAB iPLNPs to conduct applied research on mRNA delivery and gene editing. The author chose tdTomato (tdTom) transgenic mice. When the termination signal before the tdTom gene is removed by Cre enzyme or CRISPR/Cas9, the expression of red fluorescent protein will be activated for easy detection.

The author injected a single intravenous injection of 9A1P9-5A2-SC8 iPLNPs and 9A1P9-DDAB iPLNPs with Cre mRNA to tdTom mice, and measured the editing efficiency of different cell types by flow cytometry. The editing efficiency of liver parenchymal cells is as high as 91%, and the editing efficiency of lung endothelial and epithelial cells reaches 34% and 20%, respectively. These results provide a basis for mRNA-dependent organ-specific treatment.

The author further applied organ-targeted iPLNPs to CRISPR/Cas gene editing to co-deliver Cas9 mRNA and sgRNA. After an intravenous administration, liver-targeted 5A2-SC8 iPLNPs and lung-targeted 9A1P9-DDAB iPLNPs successfully edited the liver and lungs of tdTom mice, maintaining organ specificity. Next, the author targeted iPLNPs to edit endogenous genes
(PTEN) capabilities were tested. In C57BL/6 mice, after a single intravenous injection of iPLNPs loaded with Cas9 mRNA and sgPTEN, not only was successfully observed organ-selective gene editing, but the lung-targeted 9A1P9-DDAB iPLNPs had a high gene editing efficiency of 28.3 in the lungs. %.

Finally, the author verified the clinical translation potential of the iPLNPs system:

1) Using microfluidic technology to prepare iPLNPs in large quantities, and maintain high mRNA delivery efficiency and organ specificity;

2) iPLNPs can be administered repeatedly to maintain high transfection efficiency;

3) iPLNPs have very low toxicity in vivo

 

 

 

 

Nature:  Nano-drug carriers have organ selectivity for delivery of mRNA and CRISPR gene editing.  

Nature:  Nano-drug carriers have organ selectivity for delivery of mRNA and CRISPR gene editing.  

(source:internet, reference only)


Disclaimer of medicaltrend.org